Back to News
Oct 20, 2025 12:00 PM

What's Going On With Summit Therapeutics Stock On Monday?

Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading lower on Monday. The company shared progress on its lead drug candidate and third-quarter financial results.

On Sunday, Summit Therapeutics shared results from the Phase 3 HARMONi-6 trial, conducted in China by its partner, Akeso Inc.

The data were presented at the European Society for Medical Oncology 2025 Congress.

The trial showed that Ivonescimab and chemo reduced the risk of progression or death by 40% compared with BeOne Medicines Inc.’s (NASDAQ:ONC) Tevimbra (tislelizumab) and chemo for locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) irrespective of PD-L1 expression.

The ivonescimab combo regimen extended the time patients lived without tumor progression by a median of 4.2 months versus the Tevimbra-based therapy, reaching 11.1 months.

The overall response ...